每日牛股追蹤 | 港股有14只股票創新高,中國中藥(00570)大漲20.5%,近一年漲幅達87.14%
截至1月3日收盤,港股有14只股票創新高,分別爲中國中藥(00570)、洛陽玻璃股份(01108)、信利國際(00732)、同仁堂科技(01666)、中集安瑞科(03899)、光大環境(00257)、東方海外國際(00316)、高偉電子(01415)、中國水務(00855)、中裕燃氣(03633)、中國建築國際(03311)、長江基建集團(01038)、國泰君安(02611)、海昌海洋公園(02255)。(注:統計港股市場上市值>100億港元、成交額>1000萬港元,上市時間>1個月的股票)
中國中藥(00570)盤中最高觸達6.34港元,創52周新高,近一年漲幅87.14%。該股收盤上漲20.5%,報6.23港元。中金對中藥及醫藥股投資評級及目標價(表)。
洛陽玻璃股份(01108)盤中最高觸達20.2港元,創歷史新高,近一年漲幅218.96%。該股收盤上漲12.2%,報19.68港元。結算日恆指靠穩,商湯首掛有支持。
信利國際(00732)盤中最高觸達3.59港元,創52周新高,近一年漲幅298.21%。該股收盤上漲11.6%,報3.56港元。
同仁堂科技(01666)盤中最高觸達9.22港元,創52周新高,近一年漲幅89.66%。該股收盤上漲9.43%,報9.17港元。中金對中藥及醫藥股投資評級及目標價(表)。
中集安瑞科(03899)盤中最高觸達12.6港元,創歷史新高,近一年漲幅178%。該股收盤上漲8.11%,報12.26港元。氫能源板塊反彈!中遊儲氫產業需求強勁,儲氫瓶及碳釺維行業迎“氫”風。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.